Today, a diverse group of global partners announced that they have made measurable progress over the past year toward achieving the goal of controlling or eliminating 10 neglected tropical diseases (NTDs) by 2020.
In 2012, the world’s leading pharmaceutical companies donated more than 1 billion NTD treatments to meet 100 percent of drug requests by endemic countries. This commitment removed a key bottleneck to effective efforts to reduce the burden of several diseases that sicken, disable, and disfigure more than one billion people in the world’s poorest communities.
More than 40 countries also delivered detailed plans to achieve NTD control in the next decade. These successes are documented in a new report, From Promises to Progress, which was released in advance of the first anniversary of the London Declaration, an event that brought public and private sector partners together to make commitments aimed at dramatically reducing the incidence of diseases caused by parasites that have historically received little attention or funding from donors.
The 10 focus diseases of the London Declaration are lymphatic filariasis, trachoma, soil transmitted helminthiases, onchocerciasis, schistosomiasis, leprosy, Guinea worm, visceral leishmaniasis, Chagas disease, and human African trypanosomiasis.
To coordinate efforts and monitor progress, partners have developed a scorecard to track pledges made toward NTD control. The London Declaration Scorecard captures progress made and where more effort is needed to reach the 2020 goals. The scorecard also sets benchmarks for success in 2013 and beyond that will help put the world on a steady trajectory toward achieving NTD control.
Also today, the World Health Organization released its second NTD report, which highlights the path to achieving the 2020 goals, identifies challenges, and proposes plans to address each disease. Together, these reports offer a clear path forward for the NTD community.